Inhibition of dengue virus through suppression of host pyrimidine biosynthesis

Qing Yin Wang, Simon Bushell, Min Qing, Hao Ying Xu, Aurelio Bonavia, Sandra Nunes, Jing Zhou, Mee Kian Poh, Paola Florez de Sessions, Pornwaratt Niyomrattanakit, Hongping Dong, Keith Hoffmaster, Anne Goh, Shahul Nilar, Wouter Schul, Susan Jones, Laura Kramer, Teresa Compton, Pei-Yong Shi

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Viral replication relies on the host to supply nucleosides. Host enzymes involved in nucleoside biosynthesis are potential targets for antiviral development. Ribavirin (a known antiviral drug) is such an inhibitor that suppresses guanine biosynthesis; depletion of the intracellular GTP pool was shown to be the major mechanism to inhibit flavivirus. Along similar lines, inhibitors of the pyrimidine biosynthesis pathway could be targeted for potential antiviral development. Here we report on a novel antiviral compound (NITD-982) that inhibits host dihydroorotate dehydrogenase (DHODH), an enzyme required for pyrimidine biosynthesis. The inhibitor was identified through screening 1.8 million compounds using a dengue virus (DENV) infection assay. The compound contains an isoxazole-pyrazole core structure, and it inhibited DENV with a 50% effective concentration (EC50) of 2.4 nM and a 50% cytotoxic concentration (CC50) of >5 μM. NITD-982 has a broad antiviral spectrum, inhibiting both flaviviruses and nonflaviviruses with nanomolar EC90s. We also show that (i) the compound inhibited the enzymatic activity of recombinant DHODH, (ii) an NITD-982 analogue directly bound to the DHODH protein, (iii) supplementing the culture medium with uridine reversed the compoundmediated antiviral activity, and (iv) DENV type 2 (DENV-2) variants resistant to brequinar (a known DHODH inhibitor) were cross resistant to NITD-982. Collectively, the results demonstrate that the compound inhibits DENV through depleting the intracellular pyrimidine pool. In contrast to the in vitro potency, the compound did not show any efficacy in the DENV-AG129 mouse model. The lack of in vivo efficacy is likely due to the exogenous uptake of pyrimidine from the diet or to a high plasma protein-binding activity of the current compound.

Original languageEnglish (US)
Pages (from-to)6548-6556
Number of pages9
JournalJournal of Virology
Volume85
Issue number13
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Dengue virus
Dengue Virus
pyrimidines
Antiviral Agents
biosynthesis
nucleosides
Flavivirus
brequinar
Nucleosides
Flaviviridae
antiviral agents
pyrazoles
uridine
guanine
Isoxazoles
protein binding
virus replication
enzymes
Ribavirin
Uridine

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Wang, Q. Y., Bushell, S., Qing, M., Xu, H. Y., Bonavia, A., Nunes, S., ... Shi, P-Y. (2011). Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. Journal of Virology, 85(13), 6548-6556. https://doi.org/10.1128/JVI.02510-10

Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. / Wang, Qing Yin; Bushell, Simon; Qing, Min; Xu, Hao Ying; Bonavia, Aurelio; Nunes, Sandra; Zhou, Jing; Poh, Mee Kian; de Sessions, Paola Florez; Niyomrattanakit, Pornwaratt; Dong, Hongping; Hoffmaster, Keith; Goh, Anne; Nilar, Shahul; Schul, Wouter; Jones, Susan; Kramer, Laura; Compton, Teresa; Shi, Pei-Yong.

In: Journal of Virology, Vol. 85, No. 13, 07.2011, p. 6548-6556.

Research output: Contribution to journalArticle

Wang, QY, Bushell, S, Qing, M, Xu, HY, Bonavia, A, Nunes, S, Zhou, J, Poh, MK, de Sessions, PF, Niyomrattanakit, P, Dong, H, Hoffmaster, K, Goh, A, Nilar, S, Schul, W, Jones, S, Kramer, L, Compton, T & Shi, P-Y 2011, 'Inhibition of dengue virus through suppression of host pyrimidine biosynthesis', Journal of Virology, vol. 85, no. 13, pp. 6548-6556. https://doi.org/10.1128/JVI.02510-10
Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. Journal of Virology. 2011 Jul;85(13):6548-6556. https://doi.org/10.1128/JVI.02510-10
Wang, Qing Yin ; Bushell, Simon ; Qing, Min ; Xu, Hao Ying ; Bonavia, Aurelio ; Nunes, Sandra ; Zhou, Jing ; Poh, Mee Kian ; de Sessions, Paola Florez ; Niyomrattanakit, Pornwaratt ; Dong, Hongping ; Hoffmaster, Keith ; Goh, Anne ; Nilar, Shahul ; Schul, Wouter ; Jones, Susan ; Kramer, Laura ; Compton, Teresa ; Shi, Pei-Yong. / Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. In: Journal of Virology. 2011 ; Vol. 85, No. 13. pp. 6548-6556.
@article{a1593a271a1b44d5ac15927a7a6ce4a5,
title = "Inhibition of dengue virus through suppression of host pyrimidine biosynthesis",
abstract = "Viral replication relies on the host to supply nucleosides. Host enzymes involved in nucleoside biosynthesis are potential targets for antiviral development. Ribavirin (a known antiviral drug) is such an inhibitor that suppresses guanine biosynthesis; depletion of the intracellular GTP pool was shown to be the major mechanism to inhibit flavivirus. Along similar lines, inhibitors of the pyrimidine biosynthesis pathway could be targeted for potential antiviral development. Here we report on a novel antiviral compound (NITD-982) that inhibits host dihydroorotate dehydrogenase (DHODH), an enzyme required for pyrimidine biosynthesis. The inhibitor was identified through screening 1.8 million compounds using a dengue virus (DENV) infection assay. The compound contains an isoxazole-pyrazole core structure, and it inhibited DENV with a 50{\%} effective concentration (EC50) of 2.4 nM and a 50{\%} cytotoxic concentration (CC50) of >5 μM. NITD-982 has a broad antiviral spectrum, inhibiting both flaviviruses and nonflaviviruses with nanomolar EC90s. We also show that (i) the compound inhibited the enzymatic activity of recombinant DHODH, (ii) an NITD-982 analogue directly bound to the DHODH protein, (iii) supplementing the culture medium with uridine reversed the compoundmediated antiviral activity, and (iv) DENV type 2 (DENV-2) variants resistant to brequinar (a known DHODH inhibitor) were cross resistant to NITD-982. Collectively, the results demonstrate that the compound inhibits DENV through depleting the intracellular pyrimidine pool. In contrast to the in vitro potency, the compound did not show any efficacy in the DENV-AG129 mouse model. The lack of in vivo efficacy is likely due to the exogenous uptake of pyrimidine from the diet or to a high plasma protein-binding activity of the current compound.",
author = "Wang, {Qing Yin} and Simon Bushell and Min Qing and Xu, {Hao Ying} and Aurelio Bonavia and Sandra Nunes and Jing Zhou and Poh, {Mee Kian} and {de Sessions}, {Paola Florez} and Pornwaratt Niyomrattanakit and Hongping Dong and Keith Hoffmaster and Anne Goh and Shahul Nilar and Wouter Schul and Susan Jones and Laura Kramer and Teresa Compton and Pei-Yong Shi",
year = "2011",
month = "7",
doi = "10.1128/JVI.02510-10",
language = "English (US)",
volume = "85",
pages = "6548--6556",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "13",

}

TY - JOUR

T1 - Inhibition of dengue virus through suppression of host pyrimidine biosynthesis

AU - Wang, Qing Yin

AU - Bushell, Simon

AU - Qing, Min

AU - Xu, Hao Ying

AU - Bonavia, Aurelio

AU - Nunes, Sandra

AU - Zhou, Jing

AU - Poh, Mee Kian

AU - de Sessions, Paola Florez

AU - Niyomrattanakit, Pornwaratt

AU - Dong, Hongping

AU - Hoffmaster, Keith

AU - Goh, Anne

AU - Nilar, Shahul

AU - Schul, Wouter

AU - Jones, Susan

AU - Kramer, Laura

AU - Compton, Teresa

AU - Shi, Pei-Yong

PY - 2011/7

Y1 - 2011/7

N2 - Viral replication relies on the host to supply nucleosides. Host enzymes involved in nucleoside biosynthesis are potential targets for antiviral development. Ribavirin (a known antiviral drug) is such an inhibitor that suppresses guanine biosynthesis; depletion of the intracellular GTP pool was shown to be the major mechanism to inhibit flavivirus. Along similar lines, inhibitors of the pyrimidine biosynthesis pathway could be targeted for potential antiviral development. Here we report on a novel antiviral compound (NITD-982) that inhibits host dihydroorotate dehydrogenase (DHODH), an enzyme required for pyrimidine biosynthesis. The inhibitor was identified through screening 1.8 million compounds using a dengue virus (DENV) infection assay. The compound contains an isoxazole-pyrazole core structure, and it inhibited DENV with a 50% effective concentration (EC50) of 2.4 nM and a 50% cytotoxic concentration (CC50) of >5 μM. NITD-982 has a broad antiviral spectrum, inhibiting both flaviviruses and nonflaviviruses with nanomolar EC90s. We also show that (i) the compound inhibited the enzymatic activity of recombinant DHODH, (ii) an NITD-982 analogue directly bound to the DHODH protein, (iii) supplementing the culture medium with uridine reversed the compoundmediated antiviral activity, and (iv) DENV type 2 (DENV-2) variants resistant to brequinar (a known DHODH inhibitor) were cross resistant to NITD-982. Collectively, the results demonstrate that the compound inhibits DENV through depleting the intracellular pyrimidine pool. In contrast to the in vitro potency, the compound did not show any efficacy in the DENV-AG129 mouse model. The lack of in vivo efficacy is likely due to the exogenous uptake of pyrimidine from the diet or to a high plasma protein-binding activity of the current compound.

AB - Viral replication relies on the host to supply nucleosides. Host enzymes involved in nucleoside biosynthesis are potential targets for antiviral development. Ribavirin (a known antiviral drug) is such an inhibitor that suppresses guanine biosynthesis; depletion of the intracellular GTP pool was shown to be the major mechanism to inhibit flavivirus. Along similar lines, inhibitors of the pyrimidine biosynthesis pathway could be targeted for potential antiviral development. Here we report on a novel antiviral compound (NITD-982) that inhibits host dihydroorotate dehydrogenase (DHODH), an enzyme required for pyrimidine biosynthesis. The inhibitor was identified through screening 1.8 million compounds using a dengue virus (DENV) infection assay. The compound contains an isoxazole-pyrazole core structure, and it inhibited DENV with a 50% effective concentration (EC50) of 2.4 nM and a 50% cytotoxic concentration (CC50) of >5 μM. NITD-982 has a broad antiviral spectrum, inhibiting both flaviviruses and nonflaviviruses with nanomolar EC90s. We also show that (i) the compound inhibited the enzymatic activity of recombinant DHODH, (ii) an NITD-982 analogue directly bound to the DHODH protein, (iii) supplementing the culture medium with uridine reversed the compoundmediated antiviral activity, and (iv) DENV type 2 (DENV-2) variants resistant to brequinar (a known DHODH inhibitor) were cross resistant to NITD-982. Collectively, the results demonstrate that the compound inhibits DENV through depleting the intracellular pyrimidine pool. In contrast to the in vitro potency, the compound did not show any efficacy in the DENV-AG129 mouse model. The lack of in vivo efficacy is likely due to the exogenous uptake of pyrimidine from the diet or to a high plasma protein-binding activity of the current compound.

UR - http://www.scopus.com/inward/record.url?scp=80051822664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051822664&partnerID=8YFLogxK

U2 - 10.1128/JVI.02510-10

DO - 10.1128/JVI.02510-10

M3 - Article

VL - 85

SP - 6548

EP - 6556

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 13

ER -